<DOC>
	<DOCNO>NCT02763475</DOCNO>
	<brief_summary>The main goal study evaluate anti-relapse prophylactic activity inoculate Natural Killer ( NK ) cell consolidation therapy acute myeloid leukemia paediatric patient cytologic remission . The patient include intermediate risk relapse indication allogeneic hematopoietic stem cell transplantation . After standard induction consolidation chemotherapy treatment , patient receive five day fludarabine try kill minimal residual disease prevent NK cell rejection . Two different NK cell infusion perform within one week ( day 0 7 ) . Interleukin 2 ( IL-2 ) administrate increase cytotoxic activity NK cell .</brief_summary>
	<brief_title>NK Cells Consolidation Therapy Acute Myeloid Leukemia Children/Adolescents</brief_title>
	<detailed_description>Hypothesis : NK cell natural defence cancer cell . Thus , supplement compatible NK cell related donor might increase probability eliminate residual chemotherapy resistant cell Acute myelogenous leukemia patient . Description : NK cell donate compatible family member certain genetic code blood , call HLA , partly match patient genetic code , reduce potential rejection . Interleukin-2 co administrate NK cell treatment improve effectiveness . Methodology : The day patient receive first NK cell infusion call day 0 . The day call minus day ( -D ) . Conversely , day NK cell infusion call plus day ( +D ) . Study administration - After standard chemotherapy treatment acute myeloid leukemia ( AML ) restoration haematologic normal level , patient receive 60mg/kg cyclophosphamide ( day -6 ) five daily intravenous cycle 25 mg/m2 chemotherapic fludarabine every day ( day -5 , -4 , -3 , -2 , -1 ) . - Day 0 settle 24h 48h fludarabine treatment completion . NK cell intravenous administer twice ( day 0 day 7 ) . The first dose NK cell ( day 0 ) contain 5x10^7 cells/kg immunophenotype NK ( CD3-CD56+ ) . The second dose might higher ( 5x10^8 cells/kg ) case treatment relate toxicity first NK injection . In case , 1x10^6 cells/kg immunophenotype T ( CD56-CD3+ ) administrate . - From day 0 , IL-2 1x10^6 UI/m2 subcutaneous administrate three time week two week . Study visit Before treatment bone marrow aspirate analyze order evaluate minimal residue disease ( cytology , cytometry and/or molecular study ) least one month NK injection . objective response rate reevaluate least year . Before treatment start : - Birthday , gender personal medical history record - physical examination , include measurement vital sign ( temperature , heart breathing rate , etcâ€¦ ) - Blood urine test - Bone marrow aspirate order evaluate basal disease On every visit - Physical examination vital sign record - Adverse event form - Other concomitant drug After NK treatment - It 11 visit day +30 , +60 , +90 , +180 , +270 , +360 , +480 , +600 , +720 , +900 , +1080 include blood urine test Lansky/karnofsky scale . - Additionally day +30 , +360 , +720 +1080 bone marrow aspirate perform evaluate relapse . Length study : Up 35 AML patient include study 32 month recruitment period patient follow-up thirty-six month . The maximum length study six year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Patients age 0 21 year , diagnose AML first cytological remission complete induction consolidation chemotherapy phase criterion allogeneic hematopoietic stem cell transplantation ( HSCT ) , ie patient respond well induction lack donor HLA identical relative highrisk cytogenetic abnormality . 2 . Karnofsky Lansky Performance Scale ( PS ) &gt; 60 % 3 . Mildmoderate ( &lt; 4 ) organ functional impairment ( liver , kidney , respiratory ) accord criteria National Cancer Institute ( NCI CTCAE v4 ) . 4 . Left ventricular ejection fraction &gt; 39 % 5 . Adult subject voluntarily sign informed consent first study intervention . 6 . Minor subject whose representative / legal guardian voluntarily sign informed consent first study intervention . 7 . For mature minor ( 12 17 year old ) , addition consent sign legal guardian , assent child obtain . 8 . Women childbearing potential must negative pregnancy test time inclusion must agree use highly effective contraceptive method ( diaphragms plus spermicide male condom plus spermicide , combine oral contraceptive second method contraceptive implant , injectable contraceptive , permanent intrauterine device , sexual abstinence partner vasectomy ) participate study 30 day last visit . 9 . Presence haploidentical donor 1 . Patients history poor treatment compliance 2 . Patients psychosocial assessment censor unfit procedure : Sociofamiliar situation precludes proper participation study . Patients emotional psychological problem secondary illness PTSD , phobia , delusion , psychosis , require assistance specialist . Evaluation involvement family patient 's health . Inability understand information trial . 3 . Severe ( 4 ) organ functional impairment ( liver , kidney , respiratory ) accord criteria National Cancer Institute ( NCI CTCAE v4 ) . 4 . They consider contraindication , interaction , precaution use dose reduction indicate respective data sheet . 5 . Subjects administer investigational drug within 90 day prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Killer Cells , Natural</keyword>
	<keyword>Consolidation treatment</keyword>
	<keyword>cytologic remission</keyword>
	<keyword>Haploidentical NK Cells</keyword>
	<keyword>allogeneic</keyword>
	<keyword>IL-2 Expanded NK Cells</keyword>
</DOC>